Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Triple Negative Breast Neoplasms × bicalutamide × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 35 Triple Negative Breast Neoplasms 1 Sexual Dysfunction, Physiological 1 Neoplasm Metastasis 1

Interventions

Paclitaxel 16 Carboplatin 16 Capecitabine 13 Gemcitabine 11 130-nm albumin-bound paclitaxel 11 pembrolizumab 10 Cyclophosphamide 8 atezolizumab 6 Epirubicin 6 sacituzumab govitecan 5 eribulin 5 Vinorelbine 4 Drug Therapy 4 Doxorubicin 4 Albumin-Bound Paclitaxel 4 Docetaxel 3 Cisplatin 3 camrelizumab 2 Injections 2 Everolimus 2 veliparib 1 trilaciclib 1 toripalimab 1 taxane 1 pegfilgrastim 1 niraparib 1 ipatasertib 1 iniparib 1 famitinib 1 capivasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03055312 2021-01-28

SYSUCC-007

Sun Yat-sen University

Phase 3 Terminated

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡